Dr. Kenan Onel and his colleagues have recently discovered View a University of Chicago press release about this study.variations that can predict the risk for developing secondary cancers in pediatric patients undergoing therapy for Hodgkin’s . Nearly 20 percent of these patients develop secondary cancers within 30 years of treatment. Dr. Onel found that secondary cancers were strongly associated with genetic variations resulting in decreased expression of the PRDM1 after radiation exposure. These findings indicate a role for PRDM1 as a radiation-responsive tumor suppressor, and are important for understanding the development of secondary tumors in patients treated with radiation therapy.
Through the generous support of the Cancer Research Foundation, University of Chicago researchers are making significant progress toward deciphering the genetic complexities of therapy-related acute(t-AML) using a approach. Over the past year, six talented and multi-disciplinary teams of scientists and clinicians have gained considerable insight into the biology of t-AML and are using this information to develop improved treatment strategies.